Bridge Biotherapeutics will present at BIO 2023 International Convention

SEONGNAM, South Korea And CAMBRIDGE, Mass., May 29, 2023 /PRNewswire/ — Bridge Biotherapeutics Inc. (KQ288330), a South Korean clinical-stage biotechnology company focused on developing novel drugs for cancer, fibrosis and inflammation, is to make a company presentation on Tuesday, June 6 at the International Convention BIO 2023 which takes place in Boston, MAbetween June 5 – 8, 2023.

Pavel Printsev, Director of Business Development, will provide an up-to-date overview of the company as well as an introduction to its clinical-stage assets:

• Oncology: BBT-176 and BBT-207 (Fourth generation EGFR TKI for non-small cell lung cancer active against C797S resistance mutations)
• Pneumology: BBT-877 (Autotaxin Inhibitor for Idiopathic Pulmonary Fibrosis)

Earlier this year, the company announced the acquisition of a diagnostics company with new biosensing technology. The company’s presentation should include an introduction to the newly acquired biosensing technology and business prospects.

“We are excited to share the progress of clinical assets as well as new business activities through an in-person presentation at this year’s BIO International conference, following last year’s event. We look forward to advancing our new research and development pipeline with a focus on oncology and pulmonology,” said Pavel Printsev, Business Development Manager, Bridge Biotherapeutics.

To find out more about this session, please visit the events page on our website at https://bit.ly/3lEGVDY.

• Date and hour : Tuesday, June 6, 2023, 3:15 PM (ET)
• Place: Bedroom 104B
• Therapeutic category: Multiple therapies

About Bridge Biotherapeutics

Bridge Biotherapeutics Inc., based in the Republic of Korea and the United States, is a publicly traded clinical-stage biotechnology company founded in 2015. Bridge Biotherapeutics is engaged in the discovery and development of novel therapies, focusing on therapeutic areas needs, including ulcerative colitis, fibrotic diseases and cancers. The company is developing BBT-401, a first Pellino-1 inhibitor for the treatment of ulcerative colitis, BBT-877, a novel autotaxin inhibitor for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF), BBT-176 and BBT-207, potent targeted cancer therapies for non-small cell lung cancer (NSCLC) with EGFR C797S mutations. Learn more about https://www.bridgebiorx.com/fr/.

SOURCEBridge Biotherapeutics, Inc.